Neurology Pipeline
Valeant's Neurology pipeline compound, retigabine, is a neuronal potassium channel opener for the adjunctive treatment of partial-onset seizures in adult patients with refractory epilepsy. Retigabine has been evaluated in two large, completed Phase III trials conducted in patients with refractory epilepsy receiving treatment with up to three antiepileptic drugs (AEDs). In August 2008, Valeant and GlaxoSmithKline (GSK) entered into an exclusive worldwide collaboration agreement for retigabine. Valeant and GSK filed a New Drug Application in the U.S. and a Marketing Authorization Application in Europe in 2009.
In August 2008, Valeant and GlaxoSmithKline (GSK) entered into an exclusive worldwide collaboration agreement for retigabine, a neuronal potassium channel opener for the adjunctive treatment of partial-onset seizures in adult patients with refractory epilepsy. Valeant and GSK filed a New Drug Application in the U.S. and a Marketing Authorization Application in Europe in 2009.
